US5207710A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method for improving implant fixation
Assignee: Neucoll Inc
•
Filing: 1992-01-10
•
Granted: 1993-05-04
•
Expires: 2012-01-10
Abstract
Abstract Stress-bearing prostheses for replacement or partial replacement of stress-bearing bone are fixed in place by bony ingrowth by providing a stress-bearing member having a porous region in combination with an osteogenic factor extract or a purified osteogenic inductive protein, optionally in combination with a TGF-beta cofactor, in a pharmaceutically acceptable carrier. The carrier is preferably either a collagen composition or a ceramic.
Inventors
- 👤 George H. Chu
- 👤 Rosa Armstrong
- 👤 Robert Chang
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 01:57
CPC Classifications
A; A61; A61F; A61F2/00; A61F2/02; A61F2/28; A61L; A61L27/00; A61L27/14; A61L27/22; A61L27/227; A61L27/50; A61L27/56; A61F2/30; A61F2002/30001; A61F2002/30003; A61F2002/30004; A61F2002/30032; A61F2002/30667; A61F2002/30677; A61F2250/00; A61F2250/0014; A61F2250/003; A61F2250/0031; A61F2250/0058; A61F2250/0067; A61L2430/00; A61L2430/02; Y; Y10; Y10S; Y10S623/00; Y10S623/92; Y10S623/923
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
84 words
A method for permanently fixing a stress-bearing bone-replacement prosthesis having a stress-bearing member by inducing bony ingrowth into the stress-bearing member, where said prosthesis is implanted in a site in a subject, wherein said method comprises: administering to the site in the subject a substantially pure osteogenically active protein and an effective amount of a transforming growth factor of the beta type in a pharmaceutically acceptable carrier wherein the osteogenic protein and carrier are present in a weight ratio of about 1:5,000 to 1:50,000.
Claim 2
Independent Claim
84 words
A method for permanently fixing a stress-bearing bone-replacement prosthesis having a stress-bearing member by inducing bony ingrowth into the stress-bearing member, where said prosthesis is implanted in a site in a subject, wherein said method comprises: administering to the site in the subject a substantially pure osteogenically active protein and an effective amount of a transforming growth factor of the beta type in a pharmaceutically acceptable carrier wherein the osteogenic protein and carrier are present in a weight ratio of about 1:5,000 to 1:50,000.
Claim 3
Dependent Claim
28 words
The method of claim 1 wherein the osteogenic protein and transforming growth factor of the beta type are present in a weight ratio of about 10:1 to 1:10.
Claim 4
Dependent Claim
12 words
The method of claim 1 wherein the pharmaceutically acceptable carrier comprises collagen.
Claim 5
Dependent Claim
13 words
The method of claim 1 wherein the pharmaceutically acceptable carrier is a ceramic.
Claim 6
Dependent Claim
22 words
The method of claim 4 wherein the ceramic is selected from the group consisting of hydroxyapatite, tricalcium phosphate, and a mixture thereof.
Claim 7
Independent Claim
63 words
A method for repairing bone defects comprising: administering to a site of a bone defect a bone replacement composition comprising a substantially pure osteogenically active protein and an effective amount of transforming growth factor of the beta-type in a pharmaceutically acceptable carrier, and a stress-bearing member wherein the osteogenic protein and carrier are present in a weight ratio of about 1:5,000 to 1:50,000.
Claim 8
Independent Claim
63 words
A method for repairing bone defects comprising: administering to a site of a bone defect a bone replacement composition comprising a substantially pure osteogenically active protein and an effective amount of transforming growth factor of the beta-type in a pharmaceutically acceptable carrier, and a stress-bearing member wherein the osteogenic protein and carrier are present in a weight ratio of about 1:5,000 to 1:50,000.
Claim 9
Dependent Claim
31 words
The method of claim 6 wherein the stress-bearing member is comprised of a material selected from the group consisting of titanium, stainless steel, an alloy containing titanium, cobalt, chromium, and molybdenum.
Claim 10
Dependent Claim
28 words
The method of claim 6 wherein the osteogenic protein and transforming growth factor of the beta type are present in a weight ratio of about 10:1 to 1:10.
Claim 11
Dependent Claim
13 words
The method of claim 6 wherein the pharmaceutically acceptable carrier comprises a ceramic.
Claim 12
Dependent Claim
13 words
The method of claim 6 wherein the pharmaceutically acceptable carrier comprises a ceramic.
Claim 13
Dependent Claim
22 words
The method of claim 10 wherein the ceramic is selected from the group consisting of hydroxyapatite, tricalcium phosphate, and a mixture thereof.
Claim 14
Independent Claim
105 words
A method for fixing a stress-bearing bone-replacement prothesis to a bone, comprising the steps of: implanting the stress-bearing bone-replacement prothesis in a patient so as to contact bone of the patient wherein transforming growth factor of the beta type and osteogenic factor extract are in a pharmaceutically acceptable carrier and are homogeneously dispersed into pores of the prothesis; and allowing the prothesis to remain in contact with the bone until bone growth into the pores occurs fixing the prothesis to the bone wherein the osteogenic factor extract and transforming growth factor of the beta type are present in a weight ratio of 10:1 to 1:10.
Claim 15
Independent Claim
105 words
A method for fixing a stress-bearing bone-replacement prothesis to a bone, comprising the steps of: implanting the stress-bearing bone-replacement prothesis in a patient so as to contact bone of the patient wherein transforming growth factor of the beta type and osteogenic factor extract are in a pharmaceutically acceptable carrier and are homogeneously dispersed into pores of the prothesis; and allowing the prothesis to remain in contact with the bone until bone growth into the pores occurs fixing the prothesis to the bone wherein the osteogenic factor extract and transforming growth factor of the beta type are present in a weight ratio of 10:1 to 1:10.
References Cited (Backward Citations)
US3929971A
Cited
US4599085A
Cited
US4356572A
Cited
FR2564732A1
Cited
GB2164042A
Cited
US4774322A
Cited
US4774228A
Cited
US4888366A
Cited
US5001169A
Cited
US4863732A
Cited
US4968590A
Cited
US4976736A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-05-03 | 1996-11-02 | 1997-05-04 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-05-03 | 2000-11-02 | 2001-05-04 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-05-03 | 2004-11-02 | 2005-05-04 | $7700.00 | Window Closed / Lapsed |